טמו 180 מ"ג
Country: Israel
Language: Hebrew
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
TEMOZOLOMIDE 180 MG
Available from:
PERRIGO ISRAEL AGENCIES LTD
ATC code:
L01AX03
Pharmaceutical form:
CAPSULES
Administration route:
PER OS
Manufactured by:
HAUPT PHARMA AMAREG GMBH, GERMANY
Therapeutic group:
TEMOZOLOMIDE
Therapeutic indications:
Temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
Authorization date:
2011-11-01
